Archives: Agenda

The Intelligent Cold Chain: How Precision Logistics Are Unlocking Global Trials for Next-Generation Therapies 智能冷链：精准物流如何解锁下一代疗法的全球试验

The advent of “living drugs” has made the clinical supply chain a critical factor in clinical trial success, requiring a shift from basic cold chain to data-driven precision logistics. Integrating digital intelligence into the cold chain is now essential, transforming it into a robust platform that ensures the reliable and scalable global delivery of these complex therapies.

  • From Passive Shipping to Active, Intelligent Orchestration
  • IoT, Blockchain, and the Creation of a “Digital Twin” for Every Shipment
  • Using AI to Forecast and Prevent Deviations
  • Closing the Loop from Vein-to-Vein
  • ROI on Intelligence in Risk Reduction and Speed

“活药物”时代的到来，使临床供应链从后台支持跃升为决定试验成败的关键变量。我们正面临从基础冷链向数据驱动的精准物流的根本转型。将数字智能深度整合进冷链不再是锦上添花，而是必答题——它正将脆弱的物流环节重塑为支持复杂疗法全球规模化交付的可靠平台。

  • 从被动运输到主动智能协同
  • 物联网、区块链与每一批次的“数字孪生”
  • 利用人工智能预测并规避温控偏差
  • 从静脉到静脉的全流程闭环管理
  • 智能冷链在风险降低与速度提升中的投资回报

OPENING KEYNOTE: China’s Biopharma Leap: From Fast-Follower to Global Innovator 开幕主旨演讲：中国生物医药的跨越——从快速跟跑到全球创新

China stands at an inflection point in global biopharma innovation. Having mastered the art of rapid development and commercialization as a fast-follower, the industry is now making a decisive strategic pivot towards becoming a true global innovator. The rise of China-led international multi-center trials (MRCTs) and landmark global partnerships underscores a new reality: China is no longer just a vast market or a development executor, but a primary source of scientific insight and therapeutic value.

  • From “Fast Follower” to Autonomous Innovation
  • Leveraging China’s Capabilities for Worldwide Development
  • From Local Assurance to Global Collaboration
  • Aligning Standards and Achieving Mutual Recognition
  • Building an Open, Collaborative Global Network

中国正处于全球生物医药创新的关键转折点。作为快速跟跑者，中国已熟练掌握快速研发与商业化的核心能力，如今正坚定地向真正的全球创新者战略转型。中国主导的国际多中心临床试验的崛起，以及里程碑式的全球合作伙伴关系，揭示了一个全新的现实：中国不再仅仅是一个广阔的市场或研发执行方，而正在成为科学洞见与治疗价值的重要源头。

  • 从“快速跟跑”到自主创新
  • 借力中国能力赋能全球研发
  • 从本土保障到全球协作
  • 标准互认与监管对齐
  • 构建开放协作的全球创新网络

The Next-Generation DCT Blueprint: AI-powered Network and Protocol-built Agility 下一代DCT蓝图：AI驱动网络与内嵌灵活性的方案设计

  • The “DCT-as-a-Service” Operating Model
  • The Modular Designed Protocols with “Build-in Agility”
  • The Rise of the Virtual Research Coordinator (VRC)
  • AI-Powered Feasibility & Predictive Patient Mapping

 

  • “DCT即服务”运营模式
  • 模块化方案设计与“内嵌灵活性”的方案起草
  • 虚拟研究协调员的崛起
  • AI驱动的可行性评估与预测性患者画像

CASE STUDY Clinical Trial at Warp Speed: How China Achieves 2-5x Faster Patient Enrollment 超速临床试验：中国如何实现2-5倍的患者入组效率

  • The “Mega-Site” Efficiency of Large Public Hospital Networks
  • Revolutionizing Patient Matching with National Databases & AI
  • Innovative Recruitment & End-to-End Engagement Strategies
  • The Standardized CRC Model and PI Collaboration
  • Translating the China Model for International Multi-Center Trials

 

  • 大型公立医院网络的“超级中心”效能
  • 国家数据库与人工智能驱动下的患者匹配革命
  • 创新招募策略与端到端患者 engagement 机制
  • 标准化CRC模式与研究者协同协作
  • 中国模式的国际化多中心试验移植路径

PANEL DISCUSSION: Staying Ahead of the Curve: Key Trends Transforming Clinical Trials 圆桌讨论：领跑变革浪潮——重塑临床试验的核心趋势

Clinical development is being reshaped by technology, new regulations, and a patient=centric focus. This panel will analyse key trends, from virtual trials to AI, separating hype from reality and providing a practical roadmap for leading the next generation of clinical research.

  • Practical Implementation of DCTs & Hybrid Models
  • Integrating RWE, AI, and Advanced Analytics
  • Evolving from Recruitment to True Engagement
  • Adapting SOPs, Vendor Partnerships, and Risk Management
  • Regional Variations in Adopting Next-Generation Trials

技术革新、监管变革与患者中心理念正深度重塑临床研发格局。本场圆桌将紧扣从虚拟试验到人工智能等关键趋势，去伪存真，为领跑下一代临床研究提供可落地的行动路线图。

  • DCT与混合模式如何从试点走向实操
  • 真实世界证据、人工智能与高级分析技术的深度融合
  • 从“招募患者”进阶为“真正卷入”患者
  • 标准操作规程、供应商合作与风险管理如何顺势而变
  • 下一代试验落地：不可忽视的区域差异